rss

Related ArticlesRosacea. J Dtsch Dermatol Ges. 2009 Jul 24; Authors: Gauwerky K, Klövekorn W, Korting HC, Lehmann P, Meigel EM, Reinel D, Ruzicka T, Schaller M, Schöfer H, Tietze J PMID: 19650823 [PubMed - as supplied by publisher] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related ArticlesTopical use of pimecrolimus in atopic dermatitis: Update on the safety and efficacy. J Dtsch Dermatol Ges. 2009 Jul 24; Authors: Werfel T Pimecrolimus has been approved for more than five years for the treatment of atopic dermatitis in Germany. An important difference in the safety profile of this drug compared with topical corticosteroids is the lack of potential side effects which are often observed upon prolonged use of topical corticosteroids (skin atrophy, steroid-induced rosacea or perioral dermatitis). Even after prolonged use in sensitive skin areas, no tolerance to this drug is induced, in contrast to that seen with topical corticosteroids. The most common side effect of pimecrolimus is burning. Placebo-controlled studies suggest that pimecrolimus is associated with a slightly increased incidence of herpes simplex infections. Compared with topical corticosteroids, pimecrolimus does not increase the overall incidence of skin infections (including recurrent herpes simplex infections). So far, clinical studies with pimecrolimus have not shown any evidence of an increased risk of malignancy. The analysis of spontaneously reported adverse events has also not shown any evidence of malignancy caused by pimecrolimus. This corresponds with the results of a case-control study from a large U.S. database. According to the German guidelines on atopic dermatitis, topical calcineurin inhibitors are indicated when topical corticosteroids are not indicated or when an anticipated lengthy treatment course would lead to inevitable side effects. On sensitive areas such as face, intertriginous regions and scalp, they are preferred as first-line choice over topical corticosteroids. PMID: 19650820 [PubMed - as supplied by publisher] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related ArticlesIs rosacea another disorder of gut microbes? Curr Gastroenterol Rep. 2009 Aug;11(4):253-4 Authors: Coyle WJ PMID: 19615297 [PubMed - in process] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related Articles[in Process Citation] Can J Ophthalmol. 2009 Aug;44(4):406-11 Authors: Nochez Y, Denoyer A, Pisella PJ OBJECTIVE: To evaluate the effects of topical cyclosporin A on severe and corticodependent chronic ocular surface disorders (OSD), in immune inflammatory disease. DESIGN: Experimental study, Centre hospitalier universitaire (CHU) Bretonneau, Tours, France. PARTICIPANTS: Twenty-one patients diagnosed with dry eye syndrome secondary to vernal keratoconjunctivitis (7 cases), atopic keratoconjunctivitis (8 cases), and ocular rosacea (6 cases) were treated twice a day with a 0.05% cyclosporin ophthalmic emulsion. METHODS: Corneal and conjunctival staining, Oxford score, and symptoms severity assessment (OSDI score) were conducted from the beginning of the cyclosporin treatment up to the end of study. Other collected data included visual acuity, intraocular pressure measurements, an adverse effects questionnaire, and evaluation of the use of adjunctive corticosteroids therapy. RESULTS: Topical cyclosporin 0.05% gave significant long-term improvement of visual acuity (p = 0.018), symptoms severity (OSDI score, p = 0.001), corneal and conjunctival staining (van Bijesterveld score, p = 0.0003), and Oxford score (p = 0.0002). Topical cyclosporin allowed for less corticosteroid treatment in all cases (p = 0.04), and broke it off with no long-term recurrence in 15 cases (71%). No severe adverse effect occurred, but 3 patients (14%) stopped cyclosporin treatment because of increasing ocular symptoms. CONCLUSION: Given our results, topical cyclosporin represents a new well-tolerated treatment for severe and corticodependent chronic ocular surface disorders. In monotherapy or in association with a corticotherapy, topical cyclosporin could be efficient in any OSD involving immune-based inflammation. PMID: 19606161 [PubMed - in process] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related ArticlesManagement of dysfunctional tear syndrome: a Canadian consensus. Can J Ophthalmol. 2009 Aug;44(4):385-94 Authors: Jackson WB Dry eye complaints are common, have a diverse etiology, and result from disruption of the normal tear film; hence, the term "dysfunctional tear syndrome." Recent research has shown that ocular surface disorders have an inflammatory origin, that inflammation of the ocular surface does not always manifest as "red eye," and that a patient does not have to have a systemic autoimmune disease to experience a local, ocular autoimmune event. A panel of Canadian cornea and external disease subspecialists met and developed a questionnaire and treatment algorithm to aid the comprehensive ophthalmologist. Management of ocular surface disorders begins with a review of the patient's medical history, with particular attention to medication use, and a thorough ophthalmological examination. Use of a simple questionnaire can aid in the diagnosis. A variety of treatment modalities are available, the most effective of which are those that target the underlying inflammatory process with the goal of restoring the normal tear film. A treatment algorithm is presented that matches the severity of symptoms with the intensity of treatment. Lifestyle modifications, regular hygiene, and tear supplements may be sufficient in patients with mild symptoms. Anti-inflammatory medications (topical cyclosporin A, short courses of topical steroids, and [or] oral tetracyclines) and physical measures (punctal plugs, moisture-retaining eye wear) are implemented for those with moderate-to-severe symptoms. Autologous serum tears, scleral contact lenses, and surgery are reserved for patients with severe symptoms who have an unsatisfactory response to anti-inflammatory medications. Patients with lid disease or rosacea and those with allergic conditions should be identified during the initial encounter and should receive specific therapy to relieve their symptoms. PMID: 19606158 [PubMed - in process] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related ArticlesA comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. Clin Exp Dermatol. 2009 Jul 6; Authors: Koca R, Altinyazar HC, Ankarali H, Muhtar S, Tekin NS, Cinar S Summary Background. There are various treatment options available for rosacea, depending on the subtype, but treatment is still generally unsatisfactory. Some reports have indicated beneficial effects of topical pimecrolimus. Aim. To compare the efficacy and safety of pimecrolimus 1% cream and metronidazole 1% cream in the treatment of patients with papulopustular rosacea (PR). Methods. A group of 49 patients with PR was investigated in this single-centre, randomized, open-label study. Patients were randomly assigned treatment with either pimecrolimus 1% cream or metronidazole 1% cream for 12 weeks. Response was evaluated by the inflammatory lesion count, the severity of facial erythema and telangiectasia, Physician's Global Assessment (PGA), and safety and tolerability at baseline and at weeks 3, 6, 9 and 12. Results. In total, 48 patients completed the study. Both treatments were very effective in the treatment of PR. There were no significant differences between the treatments in inflammatory lesion counts, overall erythema severity scores and PGA evaluated from baseline to week 12 (P > 0.05). Neither treatment produced any clinically relevant improvement in telangiectasia. Conclusion. Pimecrolimus cream is no more efficacious than metronidazole cream in the treatment of PR. PMID: 19594764 [PubMed - as supplied by publisher] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Red Scalp Disease - A Rosacea-Like Dermatosis of the Scalp? Successful Therapy with Oral Tetracycline. Dermatology. 2009 Jul 8; Authors: Oberholzer PA, Nobbe S, Kolm I, Kerl K, Kamarachev J, Trüeb RM PMID: 19590169 [PubMed - as supplied by publisher] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Anti-inflamatory dose doxycycline in the treatment of rosacea. J Drugs Dermatol. 2009 Jul;8(7):664-8 Authors: Del Rosso JQ Anti-inflammatory dose doxycycline (ADD), which is the administration of doxycycline 40 mg extended-release capsule once daily, is the only oral therapy approved by the United States Food and Drug Administration (FDA) for treatment of rosacea. ADD once daily has been shown to exhibit anti-inflammatory activity while not demonstrating evidence of antibiotic effects, including with chronic administration. This article summarizes the clinical studies to date on the use of ADD once daily in papulopustular rosacea, including both monotherapy and combination therapy studies. The combination therapy approach of ADD once daily and metronidazole gel 1% once daily has been shown to exhibit a more rapid onset of therapeutic effect than topical therapy alone. ADD once daily has been demonstrated to be effective in adult subjects with moderate to severe rosacea, and exhibits a favorable safety profile coupled with absence of antibiotic selection pressure. Additionally, a much lower incidence of gastrointestinal side effects has been noted with ADD once daily as compared to doxycycline 100 mg once daily. PMID: 19588643 [PubMed - in process] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol. 2009 Jul;8(7):639-48 Authors: Thiboutot DM, Fleischer AB, Del Rosso JQ, Rich P This two-phase, multicenter study was undertaken to examine the safety and efficacy of combination therapy with oral doxycycline and topical azelaic acid (AzA) 15% gel in moderate-to-severe papulopustular rosacea and to determine the effect of subsequent maintenance monotherapy with AzA 15% gel alone. In the initial open-label, non-randomized phase of the study, subjects (n=172) received topical AzA 15% gel and oral doxycycline (100 mg), both twice daily, for < or = 12 weeks. In the second, double-blind study phase, subjects who had initially undergone at least four weeks of combination treatment in phase 1 and who achieved > or = 75% inflammatory lesion count reduction (n=136) were randomized to receive either AzA 15% gel or its vehicle twice daily for an additional 24 weeks. Assessments of efficacy were obtained at four-week intervals throughout both phases of the study and included change in inflammatory lesion count, investigator global assessment (IGA) of rosacea severity, and separate assessments of erythema and telangiectasia severity. At the last visit for each phase of the study, the investigator and participant each rated overall improvement, with the participant rating cosmetic acceptability and the investigator rating treatment as "success" or "failure" based on IGA score. During the second phase of the trial, the rate of relapse -- defined as either a 50% deterioration in the lesion count improvement from phase 1, an increase in erythema intolerable to the subject or maintenance therapy failure as judged by the investigator and/or the subject -- was obtained. Safety assessments were conducted for both phases of the study and included analysis of adverse events (AEs) and a rating of cutaneous tolerability by the subject. By week 12 of the open-label phase of the study, 81.4% of subjects had reached a 75% or greater reduction in inflammatory lesion count, and 64% of patients achieved treatment success. During the second study phase (maintenance phase), AzA 15% gel consistently provided a better maintenance response than vehicle, with maintenance of remission in 75% of patients over the six-month duration of the maintenance phase. Additionally AzA 15% gel showed a statistically significantly lower deterioration in absolute inflammatory lesion counts than did vehicle after 8, 16, 20 and 24 weeks of maintenance therapy. No serious treatment-related AEs were encountered in the study, and 98.5% of subjects were satisfied with the local tolerability of both AzA gel and vehicle. PMID: 19588640 [PubMed - in process] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related ArticlesCorrelation of the severity of cutaneous rosacea with ocular rosacea. Indian J Dermatol Venereol Leprol. 2009 Jul-Aug;75(4):405-6 Authors: Keshtcar-Jafari A, Akhyani M, Ehsani AH, Ghiasi M, Lajevardi V, Baradran O, Toosi S PMID: 19584472 [PubMed - in process] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related Articles'A close shave' -- use of a disposable razor blade in the management of rhinophyma. Ann R Coll Surg Engl. 2009 Mar;91(2):167 Authors: Fishman JM, Kundu S, Draper M PMID: 19579303 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related Articles[Gigantic nasal tumor] HNO. 2009 Apr;57(4):368-70 Authors: Lehnerdt G, Oztürk E, Grabellus F A space-occupying lesion, which had been growing on the external surface of the nose of a 57-year-old man for 5 years was considered to most likely be an angiofibroma after surgical removal and histological examination, but the final clinical diagnosis was clearly a rhinophyma. This discrepancy is relevant for surgical treatment, because the vessel-rich tumor tended to substantial intraoperative bleeding. PMID: 19183915 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Intestinal alkaline phosphatase: The molecular link between rosacea and gastrointestinal disease? Med Hypotheses. 2009 Jun 30; Authors: Whitehead J Rosacea is a common inflammatory condition of the facial skin of unknown etiology, which frequently occurs in combination with gastrointestinal disorders. Many dietary and hormonal factors are known to affect the severity of rosacea symptoms, several of which also modulate the activity of the enzyme intestinal alkaline phosphatase (IAP). The role of IAP in inhibiting an inflammatory response to intestinal bacteria suggests a mechanism by which intestinal pathologies may be linked to the skin inflammation characteristic of rosacea. Analysis of alkaline phosphatase activity is routinely performed on blood samples, and methods to quantify enzyme activity of the intestinal isoform specifically have been described. Correlations between IAP activity and rosacea symptoms in patients and controls can thus be screened by noninvasive and inexpensive means. If IAP activity is found to be low in rosacea patients, acute symptoms could be treated with oral IAP supplementation, and trials of IAP-activating medications currently used in gastrointestinal disease could be initiated in rosacea patients. More importantly, the safe and long-term control of rosacea could be undertaken by patients themselves through dietary modification to naturally increase IAP activity. PMID: 19573995 [PubMed - as supplied by publisher] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article Read the full article.

Related ArticlesThe metabolism and pharmacokinetics of isotretinoin in patients with acne and rosacea are not influenced by ethanol. Br J Dermatol. 2009 May 21; Authors: Grønhøj Larsen F, Jakobsen P, Grønhøj Larsen C, Heidenheim M, Held E, Nielsen-Kudsk F Summary Background Isotretinoin is effective in the treatment of severe acne and rosacea. Both parent drug and its main metabolite 4-oxo-isotretinoin are potentially teratogenic compounds and contain a carboxylic acid moiety. In the presence of ethanol, naturally occurring as well as synthetic retinoids also containing a carboxylic acid moiety are capable of undergoing an ethyl esterification with the metabolic formation of more lipophilic compounds with a much longer terminal half-life. Objectives To determine if isotretinoin (13-cis-RA), its main metabolite 4-oxo-isotretinoin (4-oxo-13-cis-RA), and other possible metabolites in the presence or absence of ethanol are converted to their corresponding ethyl derivatives in patients with severe acne or rosacea after multiple isotretinoin dosing. In addition, pharmacokinetic parameters of the parent drug and its 4-oxo metabolite were determined. Patients/methods Eleven patients with severe acne or rosacea were treated with isotretinoin daily for 3 months and investigated pharmacokinetically during 24 h after 1 month of treatment and for up to 28 days after discontinuation of therapy. A possible influence of ethanol was evaluated using a simple self-administered questionnaire and by measuring serum ethanol levels during treatment. The concentrations of isotretinoin, 4-oxo-isotretinoin and possible ethylated and nonethylated metabolites were measured by reverse-phase high-performance liquid chromatography. Results Although seven of 11 patients had a considerable weekly alcohol intake, no endogenous synthesis of ethyl derivatives of isotretinoin, the main 4-oxo metabolite or the all-trans compounds was chromatographically detectable in any of the patients' plasma samples during the treatment period. Multiple dose pharmacokinetic data for the parent drug and its main metabolite were comparable to previous studies. Conclusions The metabolism and pharmacokinetics of isotretinoin and its main metabolites are not influenced by ethanol during long-term isotretinoin treatment. After ceasing long-term isotretinoin therapy the recommended period of 1 month for using anticonceptive measures in fertile women seems adequate. PMID: 19563582 [PubMed - as supplied by publisher] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related ArticlesRosacea: A Review. P T. 2009 Jan;34(1):38-45 Authors: Culp B, Scheinfeld N Rosacea is a chronic inflammatory condition of the facial skin affecting the blood vessels and pilosebaceous units. Rosacea is more common in persons of northern and western European descent with a fair complexion, but it can affect skin of any color. Although symptoms may wax and wane during the short term, rosacea can progress with time. Patients usually present with complaints of flushing and blushing and sensitive skin, and their skin may be especially irritated by topical preparations. Rosacea has a variety of triggers; however, they may be unnoticed by the patient.Standard treatments approved by the FDA include azelaic acid, topical metronidazole, and oral tetracyclines, in particular minocycline and doxycycline. Other topical treatments include topical clindamycin, subantimicrobial-dose doxycycline, and sulfur products. Azithromycin and controlled-release minocycline are possible options for treating rosacea, but the FDA has not approved either agent for this indication. PMID: 19562004 [PubMed - as supplied by publisher] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related ArticlesTreatment of rhinophyma with ultrasonic scalpel: case report. J Plast Reconstr Aesthet Surg. 2009 Jun;62(6):e164-5 Authors: Tenna S, Gigliofiorito P, Langella M, Carusi C, Persichetti P PMID: 19070559 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related ArticlesEfficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther. 2009 Jun 23; Authors: Schechter BA, Katz RS, Friedman LS INTRODUCTION: This study was designed to compare the efficacy of cyclosporine ophthalmic emulsion 0.05% with an artificial tear solution for the treatment of rosacea-associated eyelid and corneal pathology. METHODS: Double-masked, randomized, 3-month clinical trial of 37 patients with rosacea-associated eyelid and corneal changes (defined as lid margin telangiectasia, meibomian gland inspissation, and/or fullness of the lid margin). All findings were standardized and compared to photographs for grading. RESULTS: There was a statistically significant increase in Schirmer (with anesthesia) scores of 2.7+/-2.2 mm after 3 months of treatment in the topical cyclosporine group (P<0.001), compared with a mean decrease of -1.4+/-4.6 mm (P=0.271) in the artificial tears group. The mean tear break-up time score significantly improved in the topical cyclosporine group (mean increase of 3.56+/-1.5 seconds, P<0.001), but worsened in the control group, although this change was not significantly significant (mean decrease of -0.04+/-1.6 seconds, P=0.929). The topical cyclosporine group exhibited a significantly greater mean reduction in corneal staining scores (-1.3+/-0.53) compared with the control group (-0.2+/-0.83; between groups P<0.001). The topical cyclosporine group had a greater improvement in Ocular Surface Disease Index scores than those using artificial tears (P=0.022). Limitations of the study included an older, predominantly Caucasian patient population and short trial length. CONCLUSIONS: Topical cyclosporine 0.05% is more effective than artificial tears for the treatment of rosacea-associated lid and corneal changes. PMID: 19551353 [PubMed - as supplied by publisher] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related ArticlesRhinophymous leishmaniasis: A new variant. Dermatol Online J. 2009;15(3):10 Authors: Ul Bari A, Ejaz A Cutaneous leishmaniasis is known for its wide clinical spectrum. The nose is one of the usual sites where the disease can present in many forms, such as psoriasiform plaques, furunculoid nodules, lupoid plaques, and erysipeloid or mucocutaneous types. We present a new morphology, i.e. rhinophyma-like plaque in an elderly male patient who presented with a large infiltrated plaque involving his nose and the adjoining area of his upper lip. It appeared to be rhinophyma of the nose but was diagnosed as cutaneous leishmaniasis after the demonstration of leishmania parasites in a skin smear preparation; he was treated satisfactorily with antimonials. PMID: 19379654 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related ArticlesLow-fat and fat-free pleomorphic lipomas: a diagnostic challenge. Am J Dermatopathol. 2009 Jul;31(5):423-6 Authors: Sachdeva MP, Goldblum JR, Rubin BP, Billings SD Pleomorphic lipomas are benign tumors that most commonly present as subcutaneous masses in the head and neck, shoulder, or back region of middle-aged to elderly men. They are related to spindle cell lipomas based on shared cytogenetic aberrations and histologic features. When little or no fat is present, the diagnosis can be challenging. A review of 38 pleomorphic lipomas seen in consultation revealed 7 cases in which fat was present in reduced (<5%) amounts (n = 5) or absent (n = 2). Six of 7 cases were from men with a mean age of 59 years. Excluding 1 case where the site was not specified, they all presented as solitary well-circumscribed subcutaneous masses in the head and neck (n = 3) or shoulder (n = 2) region. The seventh case was an intradermal tumor from the nose of a 48-year-old woman. All displayed pleomorphic and multinucleated floret cells interspersed among bland spindle cells and ropey collagen. They were diffusely immunoreactive for CD34. Referring diagnoses, when provided, included myxofibrosarcoma, giant cell fibroblastoma, and granulomatous rosacea for the tumor from the nose; none considered pleomorphic lipomas. When fat is absent or present in reduced amounts, clinical context and identification of classic nonlipogenic components are essential for the diagnosis of pleomorphic lipomas. PMID: 19542913 [PubMed - in process] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related ArticlesAcupuncture in dermatology: an historical perspective. Int J Dermatol. 2009 Jun;48(6):648-52 Authors: Tan EK, Millington GW, Levell NJ Classical acupuncture focuses primarily on treating the person, and secondarily treating the illness. The "symptoms" are regarded as "branch" expressions of a "root" (constitutional) imbalance. Different root imbalances can produce the same symptoms. Five patients with eczema, for example, may reveal five distinct root imbalances and would all be treated very differently. Because acupuncture treats the whole person, it has something to offer almost every condition. In many cases, acupuncture aims to bring about a complete cure; in others, it aims to manage the problem. Acupuncture remains a substantial part of the traditional Chinese medicine, which is used to treat many conditions including acne, alopecia, dermatitis, pruritus, psoriasis, rosacea, systemic lupus erythematosus, urticaria, herpes zoster, chicken pox, impetigo, leprosy, vitiligo, and tinea. This review introduces the historical context of acupuncture within Chinese medicine and how it relates to skin disease. Specifically, a key question is, what can we learn from the ancients with regard to their use of acupuncture as part of a holistic system of medicine, and how does this relate to the practice of modern dermatology? PMID: 19538380 [PubMed - in process] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related ArticlesTopical PRK 124 (0.125%) lotion for improving the signs and symptoms of rosacea. J Drugs Dermatol. 2009 May;8(5):459-62 Authors: Ortiz A, Elkeeb L, Truitt A, Hindiyeh R, Aquino L, Tran M, Weinstein G BACKGROUND: Current treatments for acne rosacea are often associated with unsatisfactory outcomes and adverse effects. OBJECTIVE: To determine the efficacy and tolerability of a new moisturizing lotion for improving the clinical signs and symptoms of mild-to-moderate acne rosacea. METHODS: In a 12-week, open-label study, a moisturizing lotion containing furfuryl tetrahydropyranyladenine as PRK124 (0.125%, Pyratine-XR, Senetek PLC, Napa, CA) was applied twice daily to subjects with mild-to-moderate rosacea. Improvement in the appearances of erythema and papules were assessed by the treating physician. Skin barrier function was measured by transepidmal water loss after treatment. Tolerability and cosmetic outcome were evaluated by patients. RESULTS: Twenty-one participants completed the study. Overall clinical improvement was observed in 80% of subjects, with most showing mild-to-moderate improvement. Erythema, papule counts, and telangiectasia were reduced. The reduction in TEWL was significant at weeks 4 (p = 0.01), 8 (p < 005), and 12 (p < 0.001). Rosacea symptoms (burning, stinging, dryness) were progressively reduced, with reduction in dryness achieving statistical significance at weeks 4 (p = 0.035), 8 (p = 0.037) and 12 (p = 0.016). Treatments were well tolerated and cosmetic outcomes were acceptable. Treatment-induced irritation was not observed. CONCLUSION: The new moisturizing lotion containing furfuryl tetrahydropyranyladenine as PRK124 shows a continued trend toward improvement of skin barrier function and the appearances of erythema and papules associated with mild-to-moderate rosacea during 12 weeks of treatment. PMID: 19537369 [PubMed - in process] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related ArticlesHelicobacter pylori infection and dermatologic diseases. Eur J Dermatol. 2009 Jun 15; Authors: Hernando-Harder AC, Booken N, Goerdt S, Singer MV, Harder H Recent evidence suggests that Helicobacter pylori infections play a role in the pathogenesis of a variety of skin diseases. The best evidence for such a link is found for two diseases: chronic urticaria and immune thrombocytopenic purpura. Other diseases that have a purported, but not yet proven link to H. pylori are: cutaneous pruritus, Behçet's disease, nodular prurigo and lichen planus. Based on the current evidence for a relationship between H. pylori and chronic idiopathic thrombocytopenic purpura the European Helicobacter Study Group consensus 2007 recommended the eradication of Helicobacter pylori infection in affected patients. Lastly, single or few case reports have documented associations between Helicobacter pylori infection and rosacea, aphthous stomatitis, atopic dermatitis, alopecia areata, Schoenlein-Henoch purpura and Sjögren syndrome, but these are only descriptive in nature. Systematic studies examining the relationship between dermatologic entities and infection with H. pylori and documentation of the effect of H. pylori eradication are needed to further our understanding on this topic. PMID: 19527988 [PubMed - as supplied by publisher] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related ArticlesAntimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. Int J Antimicrob Agents. 2009 Jun 11; Authors: Rubinchik E, Dugourd D, Algara T, Pasetka C, Friedland HD Omiganan pentahydrochloride is a novel, synthetic, cationic, antimicrobial peptide that is being developed for the prevention of catheter-related infections and the treatment of acne and rosacea. In this study, the efficacy of topical omiganan gel was evaluated in two skin colonisation models (ex vivo pig skin and in vivo guinea pig skin). When tested in the ex vivo pig skin colonisation model, omiganan 0.1-2% gels exhibited potent dose-dependent activity against Gram-positive and Gram-negative bacteria and yeasts; the maximum effect was observed at 1-2%. No significant difference was noted in activity toward meticillin-resistant and meticillin-sensitive Staphylococcus aureus, and drug activity was not affected by the inoculum size. The antimicrobial activity of omiganan 1% gel was rapid, with a 2.7log(10)colony-forming unit (CFU)/site reduction in Staphylococcus epidermidis counts at 1h post application and a 5.2log(10)CFU/site reduction at 24h. Additional studies in the guinea pig skin colonisation model confirmed the potent antimicrobial and antifungal activities of omiganan 1% gel. In conclusion, omiganan gels have been demonstrated to be rapidly bactericidal and fungicidal, with significant dose-dependent activity against a broad spectrum of infectious organisms. These results further confirm that the drug has the potential as a topical antimicrobial agent. PMID: 19524411 [PubMed - as supplied by publisher] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related ArticlesDermatological future of european patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2009 Jun 1; Authors: Misery L, Boussetta S, Shooneman P, Taieb C Abstract Background The dermatological becoming of children presenting with atopic dermatitis (AD) is not well known. Objective We performed a study on the presence of AD and other dermatological diseases in subjects with a previous history of AD. Methods An opinion poll was conducted in eight countries through a telephone interview: Belgium, France, Germany, Greece, Italy, Portugal, Spain and Switzerland. Results Among 4369 interviewees, 12.25% declared a history of AD in infancy and 12.4% declared to suffer from a dermatological disease (27% of patients had a history of AD and 10.3% did not have it). Current declared cases of atopic eczema or contact eczema were more frequent in patients with previous history of AD (39.3% vs. 21.5%), whereas these patients appeared less affected by rosacea (2.9% vs. 7.9%). Some differences were observed between different countries. Conclusion The main interests of this study are the large number of subjects, originating from eight different countries, and its focus on the dermatological future of patients with AD, which is not limited to AD itself. Conflicts of interest Sami Boussetta, Pierre Shoonemann and Charles Taieb are employees of the Pierre Fabre Group. Laurent Misery is consultant for Abbott, Astellas, Cogniz, Galderma, Johnson & Johnson, Leo, Pierre Fabre, Schering-Plough, Stiefel, UCB, Wyeth. PMID: 19522708 [PubMed - as supplied by publisher] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Related ArticlesCoblation-assisted decortication for the treatment of rhinophyma. Laryngoscope. 2009 Jun;119(6):1082-4 Authors: Hetherington HE PMID: 19358247 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article